Gemma Sesmilo, MD; Beverly M.K. Biller, MD; Joan Llevadot, MD, PhD; Douglas Hayden, MA; Greta Hanson, BS; Nader Rifai, PhD; Anne Klibanski, MD
Growth hormone–deficient adults have increased cardiovascular mortality. Growth hormone replacement may affect cardiovascular risk. Inflammation plays an important role in atherosclerosis, and inflammatory markers are predictive of cardiovascular events.
To investigate the effect of growth hormone replacement on inflammatory and other cardiovascular risk factors.
Randomized, single-blind, placebo-controlled trial.
40 men with adult-onset growth hormone deficiency.
Growth hormone or placebo given for 18 months at a dose adjusted for normal serum insulin-like growth factor I level.
Anthropometric, hemoglobin A1c, and central fat values were assessed every 6 months. Levels of glucose, insulin, insulin-like growth factor I, and lipids were measured at 1, 3, 6, 12, and 18 months. C-reactive protein, serum amyloid polypeptide A, interleukin-6, and lipoprotein(a) levels were determined at baseline and 6 and 18 months.
C-reactive protein and interleukin-6 levels decreased in growth hormone recipients compared with placebo recipients (differences between groups, −1.9 ± 0.6 mg/L [P = 0.0027] and −1.3 ± 0.5 ng/L [P = 0.013], respectively). Changes in serum amyloid polypeptide A levels between groups did not reach statistical significance (difference between groups, −2.4 ± 1.2 mg/L; P = 0.056). Serum cholesterol levels, low-density lipoprotein cholesterol levels, and ratios of total cholesterol to high-density lipoprotein cholesterol decreased in growth hormone recipients in the first 3 months compared with placebo recipients (differences between groups, −0.86 ± 0.17 mmol/L [−33.2 ± 6.6 mg/dL] [P < 0.001], −0.63 ± 0.20 mmol/L [−24.5 ± 5.9 mg/dL] [P < 0.001], and −0.56 ± 0.26 [P = 0.040], respectively), but the decrease was not maintained from month 6 to month 18. Lipoprotein(a) levels increased (difference between groups, 22.0 ± 8.0 mg/L; P = 0.0096). Short-term increases occurred in glucose levels, insulin levels, and insulin-to-glucose ratios (differences between groups, 0.54 ± 0.16 mmol/L [9.6 ± 2.8 mg/dL] [P = 0.0018], 37.9 ± 9.6 pmol/L [P < 0.001], and 6.0 ± 1.8 [P = 0.0025], respectively), but only the increase in glucose level was maintained over the long term (difference between groups, 0.56 ± 0.17 mmol/L [10.0 ± 3.1 mg/dL]; P = 0.0026). Hemoglobin A1c values did not change. Truncal fat–to–total fat ratios decreased (difference between groups, −0.018 ± 0.007; P = 0.0087).
Long-term growth hormone replacement in men reduces levels of inflammatory cardiovascular risk markers, decreases central fat, and increases lipoprotein(a) and glucose levels without affecting lipid levels.
Sesmilo G, Biller BM, Llevadot J, et al. Effects of Growth Hormone Administration on Inflammatory and Other Cardiovascular Risk Markers in Men with Growth Hormone Deficiency: A Randomized, Controlled Clinical Trial. Ann Intern Med. 2000;133:111–122. doi: https://doi.org/10.7326/0003-4819-133-2-200007180-00010
Download citation file:
Published: Ann Intern Med. 2000;133(2):111-122.
Cardiology, Coronary Risk Factors, Neurology, Prevention/Screening.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use